Elevated serum level of interleukin-32α in the patients with myasthenia gravis

Sang Jun Na, Seon Hwa So, Kee Ook Lee, Young Chul Choi

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

A new cytokine, interleukin-32 (IL-32), has been implicated in the pro-inflammatory immune responses in several autoimmune disorders, such as rheumatoid arthritis and inflammatory bowel diseases. Myasthenia gravis (MG) is a well-characterized autoimmune disease directed at the postsynaptic acetylcholine receptor (AChR) or end plate of the neuromuscular junction. IL-32 is a cytokine that induces tumor necrosis factor (TNF)-α, IL-6, IL-1β, and chemokine. IL-6, TNF-α, and IL-2 are related to the pathogenesis and immunoregulation of MG. The gene expression of IL-32 is increased in human natural killer (NK) cells and T lymphocytes when stimulated by IL-2 or mitogen. NK cells influence the development of experimental autoimmune MG (EAMG) and possibly MG. The aim of this study was to examine whether IL-32α levels are increased in patients with MG and to investigate the relationship between IL-32α levels and disease activity in human MG. Serum IL-32α levels were significantly higher in the MG patients (p = 0.03): 460.07 ± 192.30 pg/mL in MG patients and 248.45 ± 188.42 pg/mL in the healthy control group. Although there was no significant statistical difference, serum IL-32α levels of patients with both anti-AChR binding and blocking antibodies trended to be higher than those without either antibodies (521.56 ± 212.92 pg/mL vs. 339.52 ± 182.78 pg/mL, p = 0.16). IL-32α serum levels tended to decrease with clinical improvement in generalized MG. This study suggests the possibility that IL-32 might contribute to MG pathogenesis or immunoregulation.

Original languageEnglish
Pages (from-to)1865-1870
Number of pages6
JournalJournal of Neurology
Volume258
Issue number10
DOIs
Publication statusPublished - 2011 Oct 1

Fingerprint

Interleukins
Myasthenia Gravis
Serum
Cholinergic Receptors
Natural Killer Cells
Interleukin-2
Interleukin-6
Tumor Necrosis Factor-alpha
Autoimmune Experimental Myasthenia Gravis
Cytokines
Blocking Antibodies
Neuromuscular Junction
Interleukin-1
Mitogens
Inflammatory Bowel Diseases
Chemokines
Human Activities
Autoimmune Diseases
Rheumatoid Arthritis
T-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

Na, Sang Jun ; So, Seon Hwa ; Lee, Kee Ook ; Choi, Young Chul. / Elevated serum level of interleukin-32α in the patients with myasthenia gravis. In: Journal of Neurology. 2011 ; Vol. 258, No. 10. pp. 1865-1870.
@article{f07c2fd885d94b75a9392701d688da90,
title = "Elevated serum level of interleukin-32α in the patients with myasthenia gravis",
abstract = "A new cytokine, interleukin-32 (IL-32), has been implicated in the pro-inflammatory immune responses in several autoimmune disorders, such as rheumatoid arthritis and inflammatory bowel diseases. Myasthenia gravis (MG) is a well-characterized autoimmune disease directed at the postsynaptic acetylcholine receptor (AChR) or end plate of the neuromuscular junction. IL-32 is a cytokine that induces tumor necrosis factor (TNF)-α, IL-6, IL-1β, and chemokine. IL-6, TNF-α, and IL-2 are related to the pathogenesis and immunoregulation of MG. The gene expression of IL-32 is increased in human natural killer (NK) cells and T lymphocytes when stimulated by IL-2 or mitogen. NK cells influence the development of experimental autoimmune MG (EAMG) and possibly MG. The aim of this study was to examine whether IL-32α levels are increased in patients with MG and to investigate the relationship between IL-32α levels and disease activity in human MG. Serum IL-32α levels were significantly higher in the MG patients (p = 0.03): 460.07 ± 192.30 pg/mL in MG patients and 248.45 ± 188.42 pg/mL in the healthy control group. Although there was no significant statistical difference, serum IL-32α levels of patients with both anti-AChR binding and blocking antibodies trended to be higher than those without either antibodies (521.56 ± 212.92 pg/mL vs. 339.52 ± 182.78 pg/mL, p = 0.16). IL-32α serum levels tended to decrease with clinical improvement in generalized MG. This study suggests the possibility that IL-32 might contribute to MG pathogenesis or immunoregulation.",
author = "Na, {Sang Jun} and So, {Seon Hwa} and Lee, {Kee Ook} and Choi, {Young Chul}",
year = "2011",
month = "10",
day = "1",
doi = "10.1007/s00415-011-6036-7",
language = "English",
volume = "258",
pages = "1865--1870",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "D. Steinkopff-Verlag",
number = "10",

}

Elevated serum level of interleukin-32α in the patients with myasthenia gravis. / Na, Sang Jun; So, Seon Hwa; Lee, Kee Ook; Choi, Young Chul.

In: Journal of Neurology, Vol. 258, No. 10, 01.10.2011, p. 1865-1870.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Elevated serum level of interleukin-32α in the patients with myasthenia gravis

AU - Na, Sang Jun

AU - So, Seon Hwa

AU - Lee, Kee Ook

AU - Choi, Young Chul

PY - 2011/10/1

Y1 - 2011/10/1

N2 - A new cytokine, interleukin-32 (IL-32), has been implicated in the pro-inflammatory immune responses in several autoimmune disorders, such as rheumatoid arthritis and inflammatory bowel diseases. Myasthenia gravis (MG) is a well-characterized autoimmune disease directed at the postsynaptic acetylcholine receptor (AChR) or end plate of the neuromuscular junction. IL-32 is a cytokine that induces tumor necrosis factor (TNF)-α, IL-6, IL-1β, and chemokine. IL-6, TNF-α, and IL-2 are related to the pathogenesis and immunoregulation of MG. The gene expression of IL-32 is increased in human natural killer (NK) cells and T lymphocytes when stimulated by IL-2 or mitogen. NK cells influence the development of experimental autoimmune MG (EAMG) and possibly MG. The aim of this study was to examine whether IL-32α levels are increased in patients with MG and to investigate the relationship between IL-32α levels and disease activity in human MG. Serum IL-32α levels were significantly higher in the MG patients (p = 0.03): 460.07 ± 192.30 pg/mL in MG patients and 248.45 ± 188.42 pg/mL in the healthy control group. Although there was no significant statistical difference, serum IL-32α levels of patients with both anti-AChR binding and blocking antibodies trended to be higher than those without either antibodies (521.56 ± 212.92 pg/mL vs. 339.52 ± 182.78 pg/mL, p = 0.16). IL-32α serum levels tended to decrease with clinical improvement in generalized MG. This study suggests the possibility that IL-32 might contribute to MG pathogenesis or immunoregulation.

AB - A new cytokine, interleukin-32 (IL-32), has been implicated in the pro-inflammatory immune responses in several autoimmune disorders, such as rheumatoid arthritis and inflammatory bowel diseases. Myasthenia gravis (MG) is a well-characterized autoimmune disease directed at the postsynaptic acetylcholine receptor (AChR) or end plate of the neuromuscular junction. IL-32 is a cytokine that induces tumor necrosis factor (TNF)-α, IL-6, IL-1β, and chemokine. IL-6, TNF-α, and IL-2 are related to the pathogenesis and immunoregulation of MG. The gene expression of IL-32 is increased in human natural killer (NK) cells and T lymphocytes when stimulated by IL-2 or mitogen. NK cells influence the development of experimental autoimmune MG (EAMG) and possibly MG. The aim of this study was to examine whether IL-32α levels are increased in patients with MG and to investigate the relationship between IL-32α levels and disease activity in human MG. Serum IL-32α levels were significantly higher in the MG patients (p = 0.03): 460.07 ± 192.30 pg/mL in MG patients and 248.45 ± 188.42 pg/mL in the healthy control group. Although there was no significant statistical difference, serum IL-32α levels of patients with both anti-AChR binding and blocking antibodies trended to be higher than those without either antibodies (521.56 ± 212.92 pg/mL vs. 339.52 ± 182.78 pg/mL, p = 0.16). IL-32α serum levels tended to decrease with clinical improvement in generalized MG. This study suggests the possibility that IL-32 might contribute to MG pathogenesis or immunoregulation.

UR - http://www.scopus.com/inward/record.url?scp=80054741469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054741469&partnerID=8YFLogxK

U2 - 10.1007/s00415-011-6036-7

DO - 10.1007/s00415-011-6036-7

M3 - Article

C2 - 21487807

AN - SCOPUS:80054741469

VL - 258

SP - 1865

EP - 1870

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 10

ER -